Skip to main content
. 2008 Jun 30;2(1):39–46. doi: 10.5009/gnl.2008.2.1.39

Fig. 5.

Fig. 5

Effect of intrathecal administration of NECA on zymosan-induced visceral hyperalgesia (A) and result of statistical analysis (B). NECA attenuates VMR to CRD at dose of 0.3 µg and 1.0 µg (p<0.05) but not at 0.1 µg. Both 0.3 µg, 1.0 µg of NECA produces motor weakness (*p<0.05).

NECA, 5-N-ethylcarboxyamidoadenosine; VMR, visceromotor response; CRD, colorectal distension.